Entrar/Registro  
INICIO ENGLISH
 
Cirujano General
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Cirujano General >Año 2012, No. 1


Hernández LA, Valanci AS, Murillo ZA
Lo que debe saber un cirujano general sobre el uso de toxina botulínica serotipo A
Cir Gen 2012; 34 (1)

Idioma: Español
Referencias bibliográficas: 54
Paginas: 58-64
Archivo PDF: 97.46 Kb.


Texto completo




RESUMEN

Objetivo: Presentar una revisión de la literatura médica acerca de las propiedades, características y múltiples usos de la toxina botulínica tipo A.
Sede: Hospital de Atención de Tercer Nivel.
Diseño: Revisión de la literatura.
Material y métodos: Se realizó revisión de la literatura en los servidores de Medline, Ovid y Medigraphic, con las palabras clave Botulinum toxin type A y abdominal wall hernia.
Resultados: La aplicación de la toxina botulínica tipo A, previo a la plastía abdominal permite lograr una parálisis en los músculos laterales de la pared abdominal y con ello una reducción en el tamaño del defecto herniario, lo que permite el cierre de pared abdominal con tensión mínima. Este agente biológico actúa por quimiodenervación de los músculos subyacentes.
Conclusión: La preparación preoperatoria con la infiltración de toxina botulínica serotipo A provoca una parálisis flácida de la pared y permite el avance de los colgajos laterales sin debilitarlos en su conformación anatómica; no sólo es una herramienta más para asegurar la refuncionalización sino un recurso que no debilita la pared en forma permanente y que no genera dolor postoperatorio mayor del esperado a la cirugía de plastía de pared. Esta técnica de preparación permite en el preoperatorio generar mejores condiciones para planear la cirugía y no excluye a todos los demás recursos adicionales que en el transoperatorio pudieran ser necesarios para cumplir con el propósito de refuncionalización de la pared.


Palabras clave: Toxina botulínica tipo A, hernia de pared abdominal.


REFERENCIAS

  1. Ibarra HTR, Nuño-Guzmán CM, Echeagaray-Herrera JE, Robles-Velez E, de Jesús González-Jaime J. Use of botulinum toxin type a before abdominal wall hernia reconstruction. World J Surg 2009; 33: 2553-2556.

  2. Wenzel R, Jones D, Borrego A. Comparing two botulinum toxin type A formulations using manufacturers product summaries. J Clin Pharm Ther 2007; 32: 387-402.

  3. Alonso-Navarro H, Jiménez-Jiménez FJ, Plaza-Nieto JF, Pilo-De la Fuente B, Navacerrada F, Arroyo-Solera M, et al. Treatment of severe bruxism with botulinum toxin type A. Rev Neurol 2011; 53: 73-6.

  4. Kranz G, Haubenberger D, Voller B, Psoch M, Schnider P, Auff E, Sycha T. Respective potencies of Botox and Dysport in a human skin model: a randomized, double-blind study. Mov Disord 2009; 24: 231-236.

  5. Aoki KR, Ranoux D, Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol 2006; 13: 10-19.

  6. Ascher B, Zakine B, Kestemont P, Baspeyras M, Bougara A, Niforos F, et al. Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthet Surg J 2005; 25: 365-37.

  7. Jewell ML, Monheit GD. An overview of clinical trial data on a new formulation of botulinum neurotoxin type A. Aesthet Surg J 2009; 29: S31-33.

  8. Mukai Y, Kaji R. Use of botulinum neurotoxin therapy. Brain Nerve 2011; 63: 775-84.

  9. Klein A, Carruthers A, Fagien S, Lowe N. Comparisons among botulinum toxins: an evidence-based review. Plast Reconstr Surg 2008; 121: 413-422.

  10. Karsal S, Raulin C. Do different formulations of botulinum toxin type a really have different migration characteristics? J Cosmet Dermatol 2008; 7: 230.

  11. Panjwani N, O’Keeffe R, Pickett A. Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. Botulinum J 2008; 1: 153-166.

  12. Markey A. Dysport. Dermatol Clin 2004; 22: 213-219.

  13. Pikett A, Mewies M. Serious issues relating to the clinical use of unlicensed botulinum toxin products. J Am Acad Dermatol 2009; 61: 149-150.

  14. Cliff SH, Judodihardjo H, Eltringham E. Different formulations of botulinum toxin type A have different migration characteristics: a double-blind, randomized study. J Cosmet Dermatol 2008; 7: 50-54.

  15. Flynn TC. Advances in the use of botulinum neurotoxins in facial esthetics. J Cosmet Dermatol 2012; 11: 42-50.

  16. Monheit G, Carruthers A, Brandt F, Rand R. A randomized, double blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg 2007; 33: S51-59.

  17. Karsai S, Adrian R, Hammes S, Thimm J, Raulin C. A randomized double-blind study of the effect of Botox and Dysport/Reloxin on forehead wrinkles and electromyography activity. Arch Dermatol 2007; 143: 1447-1449.

  18. Monheit G, Cohen J; Reloxin Investigational Group. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study. J Am Acad Dermatol 2009; 61: 421-425.

  19. Helmstaedter V, Wittekindt C, Huttenbrink KB, Guntinas-Lichius O. Safety and efficacy of botulinum toxin therapy in otorhinolaryngology: experience from 1,000 treatments. Laryngoscope 2008;118:790-6.

  20. Kim NH, Chung JH, Park RH, Park JB. The use of botulinum toxin type A in aesthetic mandibular contouring. Plast Reconstr Surg 2005; 115: 919-930.

  21. Brin MF. Basic and clinical aspects of BOTOX. Toxicon. 2009;54:676-82.

  22. Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A. Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm. Eur J Neurol 2009; 16: 392-398.

  23. Hernández J, Vinicius M, Arteaga A, Pascual I, Gómez FJ, et al. Manejo de la espasticidad en el niño con toxina botulínica tipo A 500 unidades. Consenso Querétaro. Plasticidad y Restauración Neurológica 2007; 6: 63-75.

  24. Heckmann M, Ceballos-Baumann A, Plewig G. Hyperhidrosis study group. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 2001; 344: 488-493.

  25. Hexsel DM, Soirefmann M, Rodriguez TC, do Prado TZ. Increasing the field effects of similar doses of Clostridium botulinum type A toxin-hem agglutinin complex in the treatment of compensatory hyperhidrosis. Arch Dermatol 2009; 145: 837-40.

  26. James R, Phillips D, Collin J. Durability of botulinum toxin injection for axillary hyperhidrosis. Br J Surg 2005; 92: 834-835.

  27. Vega G, Idrovo J, Rivas R, Zapata L, Rico-Alba I. Evaluación costo-efectividad de dos marcas comerciales de toxina bo­tulínica tipo A, en el manejo de la espasticidad por parálisis cerebral. ISPOR 1st Latin American Conference.

  28. Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R, Kollewe K. A long term follow up of botulinum toxin A in cervical dystonia. Neurol Res 2009; 31:463-466.

  29. Tsai CP, Chiu MC, Yen DJ, Guo YC, Y CL, Lee TC. Quantitative assessment of efficacy of dysport (botulinum toxin type A) in the treatment of Idiopathic blepharospasm and hemifacial spasm. Acta Neurol Taiwan 2005; 14: 61-68.

  30. Truong D, Comella C, Fernández HH, Ondo WG. Dysport bening essential blepharospasm study group. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord 2008; 14: 407-414.

  31. Hexsel D, Dal’Forno T, Hexsel C, Do Prado DZ, Lima MM. A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A. Dermatol Surg 2008; 34: 52-9.

  32. Tan EK, Chan LL, Chang HM. Severe bruxism following basal ganglia infarcts: insights into pathophysiology. J Neurol Sci 2004; 217: 229-232.

  33. IPSEN. FDA accepts for filing a biologics license application for Dysport in cervical dystonia. 2008 Paris.

  34. Wohlfarth K, Sycha T, Ranous D, Naver H, Caird D. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment? Curr Med Res Opin 2009; 25: 1573-1584.

  35. Pickett A. Dysport: Pharmacological properties and factors that influence toxin action. Toxicon 2009; 54: 683-689.

  36. Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, et al. European Consensus Panel. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 2009; 55: 100-119.

  37. Zakine B. Updates on dose conversion ratio between two botulinum toxin A preparations when injected in the sweat glands. Am J Clin Dermatol 2009; 10: 347.

  38. Heckmann M, Plewig G; Hyperhidrosis Study Group. Low-Dose efficacy of Botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study. Arch Dermatol 2005; 141: 1255-1259.

  39. Rosales RL, Bigalke H, Dressler D. Pharmacology of Botulinum toxin: differences between type A preparations. Eur J Neurol 2006; 13: 2-10.

  40. Mir P, Gilio F, Edwards M, Inghilleri M, Bhatia K, Rothwell J, Quinn N. Alteration of central motor excitability in a patient with hemi masticatory spasm after treatment with Botulinum toxin injections. Mov Disord 2005; 21: 73-78.

  41. Gelbard CM, Epstein H, Hebert A. Primary pediatric hyperhidrosis: a review of current treatment options. Pediatr Dermatol 2008; 25: 591-598.

  42. Simonetta MS, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of Dysport vs Botox in primary palmar hyperhidrosis. Br J Dermatol 2003; 149: 1041-1045.

  43. Broide RS, Cai B, Aoki KR, Francis J. Nerve terminal sprouting and neuromuscular junction formation precedes muscle recovery in BONT/A-treated rat skeletal muscle. Neuroscience abstract 2008.

  44. Singh JA. Botulinum toxin therapy for osteoarticular pain: an evidence-based review. Therapeutic Advances in Musculoskeletal Disease 2010; 2: 105-118.

  45. Marchini C, Acler M, Bolognari MA, Causero A, Volpe D, Regis D, et al. Efficacy of botulinum toxin type A treatment of functional impairment of degenerative hip joint: preliminary results. J Rehabil Med 2010; 42: 691-693.

  46. Finnerup NB, Sindrup SH, Jensen TS. Recent advances in pharmacological treatment of neuropathic pain. F1000 Med Rep 2010; 2: 52.

  47. Anderson S, Krug H. Dorman C. McGarraugh P, Frizelle S, Mahowald M. Analgesic effects of intra-articular botulinum toxin Type B in a murine model of chronic degenerative knee arthritis pain. J Pain Res 2010; 3: 161-168.

  48. Placzek R, Salem KH, Meiss LA, Siebold D, Drescher W. The key-muscle concept: a long-term low-dose injection strategy for botulinum toxin A treatment in cerebral palsy. Acta Orthop Belg 2012; 78: 111-6.

  49. Shestak KC, Edington HJ, Johnson RR. The separation of anatomic components technique for the reconstruction of massive midline abdominal wall defects: anatomy, surgical technique, applications, and limitations revisited. Plast Reconstr Surg 2000; 105: 731-738.

  50. Rohrich RJ, Lowe JB, Hackney FL, Bowman JL, Hobar PC. An algorithm for abdominal wall reconstruction. Plast Reconstr Surg 2000; 105: 202-16.

  51. Borud LJ, Grunwaldt L, Janz B, Mun E, Slavin SA. Components separation combined with abdominal wall plication for repair of large abdominal wall hernias following bariatric surgery. Plast Reconstr Surg 2007; 119: 1792-1798.

  52. Sukkar SM, Dumanian GA, Szczerba SM, Tellez MG. Challenging abdominal wall defects. Am J Surg 2001; 181: 115-121.

  53. Ennis LS, Young JS, Gampper TJ, Drake DB. The “open book” variation of component separation for repair of massive midline abdominal wall hernia. Am Surg 2003; 69: 733-743.

  54. Jernigan TW, Fabian TC, Croce MA, Moore N, Pritchard FE, Minard G, et al. Staged management of giant abdominal wall defects. Acute and long-term results. Ann Surg 2003; 238: 349-357.



>Revistas >Cirujano General >Año2012, No. 1
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019